Literature DB >> 24451386

Endothelial mineralocorticoid receptor activation enhances endothelial protein C receptor and decreases vascular thrombosis in mice.

Jérémy Lagrange1, Zhenlin Li, Céline Fassot, Mustapha Bourhim, Huguette Louis, Aurélie Nguyen Dinh Cat, Ara Parlakian, Denis Wahl, Patrick Lacolley, Fréderic Jaisser, Véronique Regnault.   

Abstract

Previous studies have shown that aldosterone, which activates the mineralocorticoid receptor (MR), promotes thrombosis in animal models. Our objective was to determine whether MR activation/expression in the vascular endothelium could modify thrombotic risk in vivo and to examine thrombin generation at the surface of aortic endothelial cells (HAECs). MR was conditionally overexpressed in vivo in vascular endothelial cells in mice (MR-EC mice) or stimulated with aldosterone in HAECs. Thrombosis after ferric chloride injury was delayed in MR-EC mice compared with controls as well as in wild-type FVB/NRj mice treated with aldosterone (60 μg/kg/d for 21 d). Thrombin generation in platelet-poor plasma did not differ between MR-EC mice and controls. In MR-EC mice, aortic endothelial cell protein C receptor (EPCR) expression was increased. Aldosterone (10(-8) M) attenuated thrombin generation at the surface of cultured HAECs, and this effect was associated with up-regulation of expression of EPCR, which promotes formation of activated protein C. Aldosterone increases EPCR expression via a transcriptional mechanism involving interaction of MR with the specificity protein 1 site. These findings demonstrate that MR activation acts on endothelial cells to protect against thrombosis in physiological conditions and that MR-mediated EPCR overexpression drives this antithrombotic property through enhancing protein C activation.

Entities:  

Keywords:  SP1; aldosterone; smooth muscle cell; thrombin; transcriptional regulation

Mesh:

Substances:

Year:  2014        PMID: 24451386     DOI: 10.1096/fj.13-238188

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  8 in total

Review 1.  30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature.

Authors:  Jennifer J DuPont; Iris Z Jaffe
Journal:  J Endocrinol       Date:  2017-07       Impact factor: 4.286

2.  Endothelial cell mineralocorticoid receptors: turning cardiovascular risk factors into cardiovascular dysfunction.

Authors:  Iris Z Jaffe; Frédéric Jaisser
Journal:  Hypertension       Date:  2014-02-24       Impact factor: 10.190

Review 3.  The endothelial mineralocorticoid receptor: mediator of the switch from vascular health to disease.

Authors:  Ana P Davel; Imran J Anwar; Iris Z Jaffe
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-03       Impact factor: 2.894

Review 4.  Aldosterone in vascular and metabolic dysfunction.

Authors:  James M Luther
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-01       Impact factor: 2.894

Review 5.  Vascular Mineralocorticoid Receptor: Evolutionary Mediator of Wound Healing Turned Harmful by Our Modern Lifestyle.

Authors:  Lauren A Biwer; Mary C Wallingford; Iris Z Jaffe
Journal:  Am J Hypertens       Date:  2019-01-15       Impact factor: 2.689

6.  Development of an Experimental Model to Study the Relationship Between Day-to-Day Variability in Blood Pressure and Aortic Stiffness.

Authors:  Camille Bouissou-Schurtz; Georges Lindesay; Véronique Regnault; Sophie Renet; Michel E Safar; Vincent Molinie; Hubert Dabire; Yvonnick Bezie
Journal:  Front Physiol       Date:  2015-12-08       Impact factor: 4.566

Review 7.  Mineralocorticoid receptor: A hidden culprit for hemodialysis vascular access dysfunction.

Authors:  Bohan Chen; Pei Wang; Andrew Brem; Lance Dworkin; Zhangsuo Liu; Rujun Gong
Journal:  EBioMedicine       Date:  2018-12-05       Impact factor: 8.143

Review 8.  Mineralocorticoid Receptors in the Pathophysiology of Vascular Inflammation and Atherosclerosis.

Authors:  Mary E Moss; Iris Z Jaffe
Journal:  Front Endocrinol (Lausanne)       Date:  2015-09-28       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.